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INTRODUCTION:  The utility of hyperbaric oxygen therapy (HBOT) in the treatment for necrotizing soft 
tissue infections (NSTI) has not been proven.  Previous studies have been subject to significant selection 
bias since HBOT is not universally available at all medical centers and there is often considerable delay 
associated with its initiation.  We examined the utility of HBOT for the treatment of NSTI in the modern 
era by isolating centers that have their own HBOT facilities. 
 
METHODS:  We queried all centers in the University Health Consortium (UHC) database from 2008 to 
2010 that have their own HBOT facilities (N=14).  Cases of NSTI were identified by ICD-9 diagnosis codes, 
which included Fournier’s gangrene (608.83), necrotizing fascitis (728.86), and gas gangrene (040.0).  
HBOT treatment status was identified by the presence (HBOT) or absence (CONTROL) of ICD-9 
procedure code (93.95).  We then risk stratified and matched our cohort by UHC’s validated severity of 
illness (SOI) score.  Comparisons were then made using univariate tests of association and multivariable 
logistic regression. 
 
RESULTS:  There were 1,583 NSTI cases at the 14 HBOT-capable centers.  117 (7%) cases were treated 
with HBOT.  Risk stratified univariate outcomes are summarized in the table.  There was no difference 
between HBOT and CONTROL groups in hospital length of stay (LOS), direct cost, complications, and 
mortality across the three less severe SOI classes (minor, moderate, and major).  However, for extreme 
SOI the HBOT group had fewer complications (45% vs. 66%; p<0.01) and fewer deaths (4% vs. 23%; 
<0.01) while there were no differences in LOS and cost.  Multivariable analysis identified age (OR 0.55; 
95% CI 0.44 – 0.68) and SOI (OR 0.29; 95% CI 0.21 – 0.40) as independent predictors of survival.  HBOT 
increased the odds of surviving the index hospitalization (OR 8.8; CI 95% 4.4 – 20.4). 
 
CONCLUSION:  At HBOT capable centers, receiving HBOT was associated with a significant survival 
benefit.  HBOT in conjunction with current practices for the treatment of NSTI can be both a cost 
effective and life saving therapy. 
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Figure 1:  Univariate Outcomes by Severity of Illness 
Treatment Status HBOT (+) HBOT (-) P-value 
Severity of Illness: MINOR 
 N=4 N=76  
Length of Stay 
(median days) 12 6 0.480 
ICU Length of Stay 
(median days) 2 0 0.105 
Hospital Direct Cost 
(mean) $22,105 $10,516 0.316 
At least 1 complication 50% 14% 0.122 
In-hospital Mortality <1% 2.5% 0.900 
Severity of Illness: MODERATE 
 N=20 N=169  
Length of Stay 
(median days) 13 10 0.510 
ICU Length of Stay 
(median days) 7 1 0.024* 
Hospital Direct Cost 
(mean) $27,578 $18,694 0.120 
At least 1 complication 55% 43% 0.348 
In-hospital Mortality 17.6% 4.9% 0.115 
Severity of Illness: MAJOR 
 N=44 N=642  
Length of Stay 
(median days) 14 13 0.68 
ICU Length of Stay 
(median days) 7 3 0.024* 
Hospital Direct Cost 
(mean) $29,005 $24,517 0.088 
At least 1 complication 41% 54% 0.117 
In-hospital Mortality 2.3% 5.9% 0.376 
Severity of Illness: EXTREME 
 N=49 N=579  
Length of Stay 
(median days) 23 19 0.147 
ICU Length of Stay 
(median days) 13 8 0.091 
Hospital Direct Cost 
(mean) $58,382 $42,635 0.156 
At least 1 complication 45% 66% 0.004* 
In-hospital Mortality 4.2% 23% <0.01* 
 
